KathrynCeciliaArbourMD

PubMed

• Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
  Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, Yingyun Wang, Matthew Holderfield, Ida Aronchik, Ian P Winters, Zeena Salman, Cristina Blaj, Marie Menard, Jens Br...> ;Cancer Discovery. 2024 Apr 9
• 1 citations
  Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
  Desai, J., Alonso, G., Kim, S., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., Guren, T., Massarelli, E., Miller, W., P...> ;Nature Medicine. 2024 Jan 1
• 2 citations
  Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
  Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Jacklynn V Egger, Hira Rizvi, Rohit Thummalapalli, Guiseppe Lamberti, Andrew Plodkowski, Ma...> ;The Oncologist. 2023 Nov 2
• 6 citations
  MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
  Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R Smith, Svitlana Kulyk, J David Lawson, ...> ;Cancer Discovery. 2023 Nov 1
• 7 citations
  Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced-Mutant Non-Small Cell Lung Cancer.
  Rohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, Bob T Li, Afsheen Iqbal, Isabel Preeshagul, Fernando C Santini, Juliana Eng, Marc Ladanyi, Soo-Ryum Yang, Rongl...> ;JCO Precision Oncology. 2023 Jun 1
• 1 citations
  The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.
  Noura J Choudhury, Jessica A Lavery, Samantha Brown, Ino de Bruijn, Justin Jee, Thinh Ngoc Tran, Hira Rizvi, Kathryn C Arbour, Karissa Whiting, Ronglai Shen, Matthew H...> ;Clinical Cancer Research. 2023 Sep 1
• 39 citations
  Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
  Justin Jee, Emily S Lebow, Randy Yeh, Jeeban P Das, Azadeh Namakydoust, Paul K Paik, Jamie E Chaft, Gowtham Jayakumaran, A Rose Brannon, Ryma Benayed, Ahmet Zehir, Mar...> ;Nature Medicine. 2022 Nov 1
• Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.
  Robert B Scharpf, Archana Balan, Biagio Ricciuti, Jacob Fiksel, Christopher Cherry, Chenguang Wang, Michele L Lenoue-Newton, Hira A Rizvi, James R White, Alexander S B...> ;Cancer Research. 2022 Nov 2
• 4 citations
  Expanding the Arsenal of Clinically ActiveG12C Inhibitors.
  Kathryn C Arbour, Piro Lito> ;Journal of Clinical Oncology. 2022 Aug 10
• 28 citations
  Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS-mutated non-small-cell lung cancer.
  B Ricciuti, J V Alessi, A Elkrief, X Wang, A Cortellini, Y Y Li, V R Vaz, H Gupta, F Pecci, A Barrichello, G Lamberti, T Nguyen, J Lindsay, B Sharma, K Felt, S J Rodig...> ;Annals of Oncology. 2022 Oct 1
• 5 citations
  Brief Report: Phase I clinical trial of trametinib and ponatinib in patients with non-small cell lung cancer harboring KRAS mutations
  Kathryn C. Arbour, Eusebio Manchado, Matthew J. Bott, Linda Ahn, Yosef Tobi, Andy Ni, Helena A. Yu, Alyssa Shannon, Marc Ladanyi, Victoria Perron, Michelle S. Ginsberg...> ;JTO Clinical and Research Reports. 2021 Nov 22
• 142 citations
  Diverse alterations associated with resistance to KRAS(G12C) inhibition
  Yulei Zhao, Yonina R. Murciano-Goroff, Jenny Y. Xue, Agnes Ang, Jessica Lucas, Trang Thi Mai, Arnaud Da Cruz Paula, Anne Y. Saiki, Deanna Mohn, Pragathi Achanta, Ann E...> ;Nature. 2021 Nov 1
• 117 citations
  Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
  Vaz, V., Biagio Ricciuti, Kathryn C. Arbour, Jessica J. Lin, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong, Jianjun Zhang, Michael Y. Tolstorukov, Yvonne Y. Li, Liam F. S...> ;Journal of Thoracic Oncology. 2021 Nov 2
• 19 citations
  Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
  Laura Mezquita, Isabel Ruth Preeshagul, Edouard Auclin, Diana Saravia, Lizza E.L. Hendriks, Hira Rizvi, Wungki Park, Ernest Nadal, Patricia Martin-Romano, Jose Carlos ...> ;European Journal of Cancer. 2021 Jul 1
• 204 citations
  Acquired Resistance to KRASG12C Inhibition in Cancer
  Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly, Viola W. Zhu, Melissa Lynne Johnson, Rebecca S. Heist, Tejas Patil, Gregory J. Riely, Josep...> ;The New England Journal of Medicine. 2021 Jun 23
• 9 citations
  KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
  Gregory D. Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sanchez-Vega, Yuan Liu, James G. Connolly, Yonina R. Murciano-Goroff, Matthew J. Bott, Prasad...> ;Clinical Cancer Research. 2021 Feb 16
• 48 citations
  Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
  Kathryn C. Arbour, Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knezevic, Glenn Heller, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Cha...> ;Clinical Cancer Research. 2021 Feb 8
• 31 citations
  Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade
  Kathryn C. Arbour, Anh Tuan Luu, Jia Luo, Hira Rizvi, Andrew J. Plodkowski, Mustafa Sakhi, Kevin B. Huang, Subba R. Digumarthy, Michelle S. Ginsberg, Jeffrey Girshman,...> ;Cancer Discovery. 2021 Jan 1
• 108 citations
  Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
  Corrin A. Wohlhieter, Allison Richards, Fathema Uddin, Christopher H. Hulton, Álvaro Quintanal-Villalonga, Axel Martin, Elisa de Stanchina, U. Bhanot, Marina Asher, Ni...> ;Cell Reports. 2020 Dec 1
• 153 citations
  COVID-19 in patients with lung cancer
  Jia Luo, Hira Rizvi, Isabel Ruth Preeshagul, Jacklynn V. Egger, David Hoyos, Chaitanya Bandlamudi, Caroline G. McCarthy, Christina Falcon, Adam J. Schoenfeld, Kathryn ...> ;Annals of Oncology. 2020 Oct 1
• 164 citations
  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
  Adam J. Schoenfeld, Hira Rizvi, Chaitanya Bandlamudi, Jennifer L. Sauter, William D. Travis, Natasha Rekhtman, Andrew J. Plodkowski, Rocio Perez-Johnston, Peter Sawan,...> ;Annals of Oncology. 2020 May 1
• 67 citations
  Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
  Justin F. Gainor, Hira Rizvi, E. Jimenez Aguilar, Ferdinandos Skoulidis, Beow Y. Yeap, Jarushka Naidoo, Sara Khosrowjerdi, Meghan J. Mooradian, Christine A. Lydon, Pet...> ;Annals of Oncology. 2020 Mar 1
• 62 citations
  Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
  Matthew D. Hellmann, Barzin Y. Nabet, Hira Rizvi, Aadel A. Chaudhuri, Daniel K. Wells, Mark Dunphy, Jacob J. Chabon, Chih Long Liu, Angela B. Hui, Kathryn C. Arbour, J...> ;Clinical Cancer Research. 2020 Jun 15
• 60 citations
  Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.
  Juan C. Osorio, Kathryn C. Arbour, Dung T. Le, Jennifer N. Durham, Andrew J. Plodkowski, Darragh Halpenny, Michelle S. Ginsberg, Peter Sawan, Joseph G. Crompton, Helen...> ;Journal of Clinical Oncology. 2019 Nov 1
• 105 citations
  Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
  E J Aguilar, B Ricciuti, J F Gainor, K L Kehl, S Kravets, S Dahlberg, M Nishino, L M Sholl, A Adeni, S Subegdjo, S Khosrowjerdi, R M Peterson, S Digumarthy, C Liu, J S...> ;Annals of Oncology. 2019 Oct 1
• Join now to see all

Journal Articles

• PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers  
  G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology

Lectures

• ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade. 
  2019 ASCO Annual Meeting - 6/1/2019